Report Highlights
The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual growth rate (CAGR) of 8.5% from 2014 to 2019.
Report Includes
- An overview of the global markets and technologies for the therapeutics for "silent" cancers.
- Analyses of global market trends, with data from 2013, 2014, and projections of CAGRs through 2019.
- Descriptions of cancers, with incidence and prevalence data for all major national markets.
- Assessments of currently available therapies.
- Evaluation of new agents now in clinical development, with likely launch timetables and estimates of potential clinical value.
- Profiles of major players in the "silent" cancer therapeutics industry.
SCOPE OF REPORT
The report discusses eight cancers described as “silent and deadly” because they are often undiagnosed until the diseases is advanced and difficult to treat. These cancers are brain, cervix, esophagus, mouth and larynx, ovary, pancreas, kidney, and lastly, liver. For each cancer, the cause, clinical course, diagnosis and treatment are described. Current drug therapy is outlined and new research activities are listed. The market is summarized and quantified for each cancer, with estimates of recent (2013) and current (2014) values for each cancer, and five-year projection to 2019. Geographically, the global market is given, with country analyses for the U.S., Japan, and five major Western European markets: Germany, France, Italy, Spain and the United Kingdom.
ANALYST'S CREDENTIALS
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the cancer marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More